Delta 4 GmbH

Autriche


 
Quantité totale PI 13
Rang # Quantité totale PI 117 044
Note d'activité PI 2,1/5.0    17
Rang # Activité PI 49 542
Classe Nice dominante Appareils et instruments scienti...

Brevets

Marques

4 0
2 0
5 0
2
 
Dernier brevet 2024 - Genistein for use in the treatme...
Premier brevet 2021 - Antiviral use of liraglutide and...
Dernière marque 2024 - Hyper-C
Première marque 2024 - Hyper-C

Industrie (Classification de Nice)

Derniers inventions, produits et services

2024 P/S Software. Provision of information relating to media communications. Updating of computer programs.
P/S Software; Unified communications software. Information relating to communications. Updating of co...
2023 Invention Novel use of glucagon-like peptide 1 (glp-1) agonist. The present invention refers to the new use...
2021 Invention Genistein for use in the treatment of focal segmental glomerulosclerosis (fsgs). The present inv...
Invention Saroglitazar and myristic acid for use in the treatment of focal segmental glomerulosclerosis (fs...
Invention Clopidogrel for use in the treatment of focal segmental glomerulosclerosis (fsgs). The present i...
Invention Clopidogrel for use in the treatment of focal segmental glomerulosclerosis (fsgs). The present in...
Invention Genistein for use in the treatment of focal segmental glomerulosclerosis (fsgs). The present inve...
Invention Antiviral use of liraglutide and gefitinib. The present invention refers to a pharmaceutical pre...
Invention Antiviral use of liraglutide and gefitinib. The present invention refers to a pharmaceutical prep...